Iovance Biotherapeutics, Inc.
LSE: 0JDK.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Frederick G. Vogt
- Employees
- 838
- Headquarters
- San Carlos, United States
- IPO year
- 2018
- Market cap
- $1.3B
- Website
- https://www.iovance.com
Loading 0JDK…
Loading profile data…Frequently asked questions about 0JDK
What does Iovance Biotherapeutics, Inc. (0JDK.L) do?
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
Where does 0JDK.L trade?
Iovance Biotherapeutics, Inc. (0JDK.L) trades on the London Stock Exchange.
What sector is 0JDK.L in?
Iovance Biotherapeutics, Inc. (0JDK.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Iovance Biotherapeutics, Inc.?
Frederick G. Vogt is the chief executive officer of Iovance Biotherapeutics, Inc. (0JDK.L).
Where is Iovance Biotherapeutics, Inc. headquartered?
Iovance Biotherapeutics, Inc. is headquartered in United States.
Does 0JDK.L pay a dividend?
Iovance Biotherapeutics, Inc. (0JDK.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0JDK.L go public?
Iovance Biotherapeutics, Inc. (0JDK.L) completed its initial public offering in 2018.